According to a recent LinkedIn post from Datavant, the company is promoting an upcoming webinar focused on validating real-world data (RWD) linkage for clinical and research applications. The session will feature experts from UCLA and Datavant discussing a recent JAMIA study, linkage accuracy, reliability, and practical methods to improve confidence in linked datasets.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights topics such as study design, performance measurement, and common challenges in validating RWD, targeting clinical researchers, epidemiologists, data scientists, life sciences teams, and healthcare leaders. For investors, this emphasis on methodological rigor in data linkage suggests Datavant is positioning itself as a technical authority in healthcare data integration, which could support product differentiation and strengthen relationships with academic and clinical stakeholders.
By aligning its offerings with peer-reviewed research and academic partners, Datavant appears to be signaling a focus on evidence-based validation of its linkage capabilities. This focus may enhance trust among enterprise customers and regulators in a market where data quality and compliance are critical, potentially supporting long-term adoption and pricing power in the healthcare and life sciences data ecosystem.